These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 31839878)

  • 1. A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host.
    Simons BW; Kothari V; Benzon B; Ghabili K; Hughes R; Zarif JC; Ross AE; Hurley PJ; Schaeffer EM
    Oncotarget; 2019 Dec; 10(64):6845-6854. PubMed ID: 31839878
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel patient-derived intra-femoral xenograft model of bone metastatic prostate cancer that recapitulates mixed osteolytic and osteoblastic lesions.
    Raheem O; Kulidjian AA; Wu C; Jeong YB; Yamaguchi T; Smith KM; Goff D; Leu H; Morris SR; Cacalano NA; Masuda K; Jamieson CH; Kane CJ; Jamieson CA
    J Transl Med; 2011 Oct; 9():185. PubMed ID: 22035283
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of FVB Myc-CaP cells as an immune competent, androgen receptor positive, mouse model of prostate cancer bone metastasis.
    Wang Y; Herroon MK; Zielske SP; Ellis L; Podgorski I; Taichman RS; Cackowski FC
    J Bone Oncol; 2021 Oct; 30():100386. PubMed ID: 34466376
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A new murine model of osteoblastic/osteolytic lesions from human androgen-resistant prostate cancer.
    Fradet A; Sorel H; Depalle B; Serre CM; Farlay D; Turtoi A; Bellahcene A; Follet H; Castronovo V; Clézardin P; Bonnelye E
    PLoS One; 2013; 8(9):e75092. PubMed ID: 24069383
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel model of bone-metastatic prostate cancer in immunocompetent mice.
    Power CA; Pwint H; Chan J; Cho J; Yu Y; Walsh W; Russell PJ
    Prostate; 2009 Nov; 69(15):1613-23. PubMed ID: 19585491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Establishing human prostate cancer cell xenografts in bone: induction of osteoblastic reaction by prostate-specific antigen-producing tumors in athymic and SCID/bg mice using LNCaP and lineage-derived metastatic sublines.
    Wu TT; Sikes RA; Cui Q; Thalmann GN; Kao C; Murphy CF; Yang H; Zhau HE; Balian G; Chung LW
    Int J Cancer; 1998 Sep; 77(6):887-94. PubMed ID: 9714059
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bone Cell Activity in Clinical Prostate Cancer Bone Metastasis and Its Inverse Relation to Tumor Cell Androgen Receptor Activity.
    Nordstrand A; Bovinder Ylitalo E; Thysell E; Jernberg E; Crnalic S; Widmark A; Bergh A; Lerner UH; Wikström P
    Int J Mol Sci; 2018 Apr; 19(4):. PubMed ID: 29670000
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Animal models of bone metastasis.
    Rosol TJ; Tannehill-Gregg SH; LeRoy BE; Mandl S; Contag CH
    Cancer; 2003 Feb; 97(3 Suppl):748-57. PubMed ID: 12548572
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Axitinib and crizotinib combination therapy inhibits bone loss in a mouse model of castration resistant prostate cancer.
    Eswaraka J; Giddabasappa A; Han G; Lalwani K; Eisele K; Feng Z; Affolter T; Christensen J; Li G
    BMC Cancer; 2014 Oct; 14():742. PubMed ID: 25277255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dickkopf-1 (DKK-1) stimulated prostate cancer growth and metastasis and inhibited bone formation in osteoblastic bone metastases.
    Thudi NK; Martin CK; Murahari S; Shu ST; Lanigan LG; Werbeck JL; Keller ET; McCauley LK; Pinzone JJ; Rosol TJ
    Prostate; 2011 May; 71(6):615-25. PubMed ID: 20957670
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel immunocompetent model of metastatic prostate cancer-induced bone pain.
    Liu Z; Murphy SF; Huang J; Zhao L; Hall CC; Schaeffer AJ; Schaeffer EM; Thumbikat P
    Prostate; 2020 Jul; 80(10):782-794. PubMed ID: 32407603
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Severe combined immunodeficient-hu model of human prostate cancer metastasis to human bone.
    Nemeth JA; Harb JF; Barroso U; He Z; Grignon DJ; Cher ML
    Cancer Res; 1999 Apr; 59(8):1987-93. PubMed ID: 10213511
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Imaging characteristic analysis of metastatic spine lesions from breast, prostate, lung, and renal cell carcinomas for surgical planning: Osteolytic versus osteoblastic.
    Reddington JA; Mendez GA; Ching A; Kubicky CD; Klimo P; Ragel BT
    Surg Neurol Int; 2016; 7(Suppl 13):S361-5. PubMed ID: 27274410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A hemi-spleen injection model of liver metastasis for prostate cancer.
    Simons BW; Dalrymple S; Rosen M; Zheng L; Brennen WN
    Prostate; 2020 Oct; 80(14):1263-1269. PubMed ID: 32761950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling Human Prostate Cancer Metastasis in Mice
    Peiffer LB; Hicks J; Sosa RY; De Marzo AM; Sfanos KS; Maynard JP
    Front Oncol; 2022; 12():877536. PubMed ID: 35574356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Subgroups of Castration-resistant Prostate Cancer Bone Metastases Defined Through an Inverse Relationship Between Androgen Receptor Activity and Immune Response.
    Ylitalo EB; Thysell E; Jernberg E; Lundholm M; Crnalic S; Egevad L; Stattin P; Widmark A; Bergh A; Wikström P
    Eur Urol; 2017 May; 71(5):776-787. PubMed ID: 27497761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis.
    Thalmann GN; Sikes RA; Wu TT; Degeorges A; Chang SM; Ozen M; Pathak S; Chung LW
    Prostate; 2000 Jul; 44(2):91-103 Jul 1;44(2). PubMed ID: 10881018
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Self-renewing Pten-/- TP53-/- protospheres produce metastatic adenocarcinoma cell lines with multipotent progenitor activity.
    Abou-Kheir W; Hynes PG; Martin P; Yin JJ; Liu YN; Seng V; Lake R; Spurrier J; Kelly K
    PLoS One; 2011; 6(10):e26112. PubMed ID: 22022528
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cancer-secreted hsa-miR-940 induces an osteoblastic phenotype in the bone metastatic microenvironment via targeting ARHGAP1 and FAM134A.
    Hashimoto K; Ochi H; Sunamura S; Kosaka N; Mabuchi Y; Fukuda T; Yao K; Kanda H; Ae K; Okawa A; Akazawa C; Ochiya T; Futakuchi M; Takeda S; Sato S
    Proc Natl Acad Sci U S A; 2018 Feb; 115(9):2204-2209. PubMed ID: 29440427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.